Mettler-Toledo International Inc.
MTD
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $27.6B
$1,358.87
▼ -0.65%
P/E
30.53
Mkt Cap
$27.6B
52-Wk Range
$1,023–$1,525
52-Week Range
$1,023.05 - $1,525.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Global distribution network
- Advanced precision engineering
- Comprehensive technological ecosystem
- Strong research and development capabilities
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expanding pharmaceutical and biotechnology markets
Value
Fairly valued vs Life Sciences Tools peers
Momentum
Strong
+17.0% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying MTD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
JUL 30, 2026
Reported EPS of $11.46 vs $10.78 consensus (+6.3% surprise). Revenue of $1.0B vs $1.0B expected (-0.0%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.3%
Revenue trend · last 8Q
—
+12%
-5%
+4%
+8%
+8%
+7%
+4%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$954.5M
$1.0B
$883.7M
$983.2M
$1.0B
$1.1B
$947.1M
$1.0B
Margins · last 8Q
Gross
63.3%
Operating
30.1%
Profit
22.7%
Wall Street consensus
9 analysts · 56% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
56%
Hold
44%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Sep 1, 2026
vs Industry
How MTD stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related